Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twenty-three analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one […]
More Stories
DOGE Says US National Science Foundation Canceling Over $325 Million in DEI Research
By Naveen Athrappully The National Science Foundation (NSF) has canceled hundreds of millions of dollars in diversity, equity, and inclusion...
Trump, Zelenskyy Meet One-on-One at Vatican Before Pope’s Funeral
By T.J. Muscaro U.S. President Donald Trump and Ukrainian President Volodymyr Zelenskyy held a brief one-on-one discussion inside St. Peter’s...
Saks Fifth Avenue to Close Store in San Francisco’s Union Square
By Jill McLaughlin Luxury department chain Saks Fifth Avenue confirmed April 25 that it will close its Union Square location...
Open Hip Joints to Avoid Knee Pain in Sitting Cross-Legged Positions
By Amber Yang Many people use meditation to relieve stress. However, if you choose to meditate while sitting in the...
Trump Says He Hopes Ukraine Will Immediately Sign Minerals Deal
By Tom Ozimek U.S. President Donald Trump said on Friday that Ukraine hasn’t signed a long-delayed rare earths agreement that...
Politicians and Pilgrims Alike Gather for Pope Francis’s Funeral
By T.J. Muscaro The sun rose high over a packed St. Peter’s Square on the morning of April 26 as...